Piramal to market PlasmaSelect’s drugs in 38 countriesJuly 2nd, 2008 - 8:56 pm ICT by IANS
Mumbai, July 2 (IANS) Pharma major Piramal Healthcare Ltd announced Wednesday that it has bought marketing rights of Germany-based PlasmaSelect AG’s blood plasma products in 38 countries for 7.7 million euros ($12.2 million). Piramal will market PlasmaSelect’s blood plasma products under the brand name Haemaccel in 38 countries, excluding Italy and Venezuela where the products were marketed under the brand name Emagel and Solucei.
At present, Piramal markets the products under the brand name Haemaccel in India and Haemageline in 17 other countries.
In 1998, the firm bought the Haemaccel-related businesses in India along with the manufacturing facility from Sanofi-Aventis, which owned Haemaccel that time. Later in 2004, Sanofi-Aventis sold its Haemaccel related rights in 76 countries to PlasmaSelect AG.
The company said at current exchange rates, the annual revenue of Haemaccel and associated brands of Piramal is 9.1 million euros.
The agreement between the two companies includes brand rights, contracts, registrations, dossiers and know-how related to Haemaccel and associated brands.
However, the agreement excludes the manufacturing facility of PlasmaSelect at Marburg, Germany. Piramal is now setting up a Haemaccel manufacturing unit at Baddi in Himachal Pradesh.
Tags: 1 million, baddi, blood plasma, brand name, contracts, current exchange rates, drugs, emagel, euros 12, haemaccel, healthcare ltd, India, italy, marburg germany, plasma products, registrations, sanofi aventis, venezuela